Page 1 | Search Results | Diabetes | American Diabetes Association

1-20 of 37

Sort by

Sort Order Select

Meeting Abstracts

1975-LB: A Single Ascending Dose Study of a Once-Monthly Liraglutide Formulation in Participants with Type 2 Diabetes

J HANS DEVRIES, TIM HEISE, GRIT ANDERSEN, ERIK WESTRIN, MARIA NEHLIN, MARIE GÅRDMARK, KRISTINE A. BÄCK, OWE R. LUHR

Diabetes 2025;74(Supplement_1):1975-LB

https://doi.org/10.2337/db25-1975-LB

Published: 20 June 2025

View articletitled, 1975-LB: A Single Ascending Dose Study of a Once-Monthly Liraglutide Formulation in Participants with Type 2 Diabetes

Meeting Abstracts

802-P: Steady-State Pharmacokinetics and Glucodynamics of Once-Weekly Insulin Efsitora Alfa (Efsitora) in Individuals with Type 2 Diabetes (T2D)

JENNIFER LEOHR, OLIVER KLEIN, TIM HEISE, JULIANA M. BUE-VALLESKEY, SUBHA SURIYAPPERUMA, MICHAEL G. CASE, DAVID G. WATERS, EDWARD J. PRATT, ERIC ZIJLSTRA, HELLE LINNEBJERG

Diabetes 2025;74(Supplement_1):802-P

https://doi.org/10.2337/db25-802-P

Published: 20 June 2025

View articletitled, 802-P: Steady-State Pharmacokinetics and Glucodynamics of Once-Weekly Insulin Efsitora Alfa (Efsitora) in Individuals with Type 2 Diabetes (T2D)

Meeting Abstracts

141-OR: Safety, Tolerability, and Clinical Effects of Dapiglutide, a Once-Weekly GLP-1R/GLP-2R Agonist

STINE JUST MAARBJERG, REBECCA ZACHARIAE, ULRIKE HÖVELMANN, NICKLAS J. JOHANSEN, JONAS U.E. LUNDAHL, LONE F. LARSEN, NANNA S. SØRENSEN, EVAN CHARLES FRARY, TIM HEISE

Diabetes 2025;74(Supplement_1):141-OR

https://doi.org/10.2337/db25-141-OR

Published: 20 June 2025

View articletitled, 141-OR: Safety, Tolerability, and Clinical Effects of Dapiglutide, a Once-Weekly GLP-1R/GLP-2R Agonist

Meeting Abstracts

1773-P: Effects of the Novel Long-Acting Amylin Analogue Petrelintide on Body Weight and Waist Circumference by Sex in a Phase 1 Trial

DAN HESSE, MINNA B. OLSEN, JON GRIFFIN, ULRIKE HÖVELMANN, STANISLAVA MACURA, THUE JOHANSEN, BERITH F. HAGEN, HELLE FRIMER-LARSEN, TIM HEISE

Diabetes 2025;74(Supplement_1):1773-P

https://doi.org/10.2337/db25-1773-P

Published: 20 June 2025

View articletitled, 1773-P: Effects of the Novel Long-Acting Amylin Analogue Petrelintide on Body Weight and Waist Circumference by Sex in a Phase 1 Trial

Meeting Abstracts

227-OR: Tirzepatide Reduces HbA1c and Body Weight Significantly More than Placebo Regardless of Insulin Sensitivity and Beta-Cell Function—Post Hoc Analysis from SURMOUNT-2

TIM HEISE, HUI WANG, CASEY J. MAST, IMANE BENABBAD, CLARE LEE, BIRONG LIAO

Diabetes 2024;73(Supplement_1):227-OR

https://doi.org/10.2337/db24-227-OR

Published: 14 June 2024

View articletitled, 227-OR: Tirzepatide Reduces HbA1c and Body Weight Significantly More than Placebo Regardless of Insulin Sensitivity and Beta-Cell Function—Post Hoc Analysis from SURMOUNT-2

Meeting Abstracts

822-P: Influence of the Functionally Selective Insulin Analog NNC-965 vs. Insulin Glargine (IGla) on Cardiac Structure and Function

JENS JORDAN, DARIUS GERLACH, HENRIK HARALDSSON, TIM HEISE, THERESA HERBRAND, KARSTEN LYBY, JENS TANK, ERICA NISHIMURA, LEONA PLUM-MOERSCHEL, ÓLÖF THÓRISDÓTTIR, LARS JOHANSSON

Diabetes 2024;73(Supplement_1):822-P

https://doi.org/10.2337/db24-822-P

Published: 14 June 2024

View articletitled, 822-P: Influence of the Functionally Selective Insulin Analog NNC-965 vs. Insulin Glargine (IGla) on Cardiac Structure and Function

Meeting Abstracts

818-P: Effects of Insulin Efsitora Alfa (Efsitora) on Frequency and Severity of Hypoglycemia (Hypo) Under Conditions of Increased Hypo Risk Compared with Glargine in Type 2 Diabetes (T2D)

TIM HEISE, GRIT ANDERSEN, EDWARD J. PRATT, JENNIFER LEOHR, TSUYOSHI FUKUDA, QIANQIAN WANG, CHRISTOF M. KAZDA, JULIANA M. BUE-VALLESKEY, RICHARD M. BERGENSTAL

Diabetes 2024;73(Supplement_1):818-P

https://doi.org/10.2337/db24-818-P

Published: 14 June 2024

View articletitled, 818-P: Effects of Insulin Efsitora Alfa (Efsitora) on Frequency and Severity of Hypoglycemia (Hypo) Under Conditions of Increased Hypo Risk Compared with Glargine in Type 2 Diabetes (T2D)

Meeting Abstracts

820-P: The Proposed Insulin Lispro Biosimilar GN1101DP Shows Pharmacokinetic (PK) and Pharmacodynamic (PD) Bioequivalence to Humalog in Caucasian and Chinese Healthy Subjects

TIM HEISE, ERIC ZIJLSTRA, GRIT ANDERSEN, STEFFEN B. SELKER, CHUN SHEN, YUN WANG

Diabetes 2023;72(Supplement_1):820-P

https://doi.org/10.2337/db23-820-P

Published: 20 June 2023

View articletitled, 820-P: The Proposed Insulin Lispro Biosimilar GN1101DP Shows Pharmacokinetic (PK) and Pharmacodynamic (PD) Bioequivalence to Humalog in Caucasian and Chinese Healthy Subjects

Meeting Abstracts

92-LB: Safety, Tolerability, and Clinical Effects of ZP8396, a Novel Long-Acting Amylin Analog—A Single Ascending Dose Trial

MINNA B. OLSEN, ULRIKE HÖVELMANN, JON GRIFFIN, KIM M. KNUDSEN, THUE JOHANSEN, DAVID KENDALL, TIM HEISE

Diabetes 2023;72(Supplement_1):92-LB

https://doi.org/10.2337/db23-92-LB

Published: 20 June 2023

View articletitled, 92-LB: Safety, Tolerability, and Clinical Effects of ZP8396, a Novel Long-Acting Amylin Analog—A Single Ascending Dose Trial

Meeting Abstracts

967-P: Evaluation of CV and SD as Glucose Variability Metrics Based on Data from the GOLD and SILVER Trials

PAVEL J. FATULLA, HENRIK IMBERG, IRL B. HIRSCH, TIM HEISE, MARCUS LIND

Diabetes 2023;72(Supplement_1):967-P

https://doi.org/10.2337/db23-967-P

Published: 20 June 2023

View articletitled, 967-P: Evaluation of CV and SD as Glucose Variability Metrics Based on Data from the GOLD and SILVER Trials

Meeting Abstracts

722-P: Tirzepatide Improves Multiple Aspects of Beta-Cell Function

ANDREA MARI, JING LI, SHWETA URVA, TIM HEISE, J. HANS DE VRIES, EDWARD J. PRATT, ROBERT J. HEINE, MELISSA K. THOMAS, ZVONKO MILICEVIC, KIEREN J. MATHER

Diabetes 2022;71(Supplement_1):722-P

https://doi.org/10.2337/db22-722-P

Published: 01 June 2022

View articletitled, 722-P: Tirzepatide Improves Multiple Aspects of Beta-Cell Function

Meeting Abstracts

714-P: Greater Improvement in Insulin Sensitivity Per Unit Weight Loss with Tirzepatide Compared with Selective GLP-1 Receptor Agonism

KIEREN J. MATHER, ANDREA MARI, JING LI, TIM HEISE, J. HANS DE VRIES, SHWETA URVA, TAMER COSKUN, ZVONKO MILICEVIC, AXEL HAUPT, MELISSA K. THOMAS

Diabetes 2022;71(Supplement_1):714-P

https://doi.org/10.2337/db22-714-P

Published: 01 June 2022

View articletitled, 714-P: Greater Improvement in Insulin Sensitivity Per Unit Weight Loss with Tirzepatide Compared with Selective GLP-1 Receptor Agonism

Meeting Abstracts

181-OR: Sympathetic Activity in Patients with Type 2 Diabetes Mellitus Treated with Empagliflozin or Hydrochlorothiazide

KARSTEN HEUSSER, JENS TANK, ANNELIE FISCHER, TIM HEISE, JENS JORDAN

Diabetes 2022;71(Supplement_1):181-OR

https://doi.org/10.2337/db22-181-OR

Published: 01 June 2022

View articletitled, 181-OR: Sympathetic Activity in Patients with Type 2 Diabetes Mellitus Treated with Empagliflozin or Hydrochlorothiazide

Meeting Abstracts

338-OR: Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People with T2D

TIM HEISE, J. HANS DE VRIES, TAMER COSKUN, SHWETA URVA, JING LI, EDWARD J. PRATT, MELISSA K. THOMAS, KIEREN J. MATHER, JULIA P. DUNN, AXEL HAUPT, ZVONKO MILICEVIC

Diabetes 2022;71(Supplement_1):338-OR

https://doi.org/10.2337/db22-338-OR

Published: 01 June 2022

View articletitled, 338-OR: Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People with T2D

Meeting Abstracts

197-OR: ADO09, a Coformulation of Insulin A21G and Pramlintide (Pram), Improves Blood Glucose Control and Reduces Body Weight in Subjects with T1D

GRÉGORY MEIFFREN, GRIT ANDERSEN, ROSY ELOY, CLAIRE MÉGRET, SUSANNE FAMULLA, CYRIL SEROUSSI, YOU-PING CHAN, MARTIN GAUDIER, OLIVIER SOULA, J. HANS DEVRIES, TIM HEISE

Diabetes 2021;70(Supplement_1):197-OR

https://doi.org/10.2337/db21-197-OR

Published: 01 June 2021

View articletitled, 197-OR: ADO09, a Coformulation of Insulin A21G and Pramlintide (Pram), Improves Blood Glucose Control and Reduces Body Weight in Subjects with T1D

Meeting Abstracts

740-P: Proposed Biosimilar Gan & Lee Insulin Glargine (GL-GLA) Shows Pharmacokinetic (PK) and Pharmacodynamic (PD) Bioequivalence (BE) to U.S.- and EU-Licensed Insulin Glargine (IG)

TIM HEISE, LEONA PLUM-MOERSCHEL, GRIT ANDERSEN, JIA LU, MICHAEL G. WILSON, ERIC ZIJLSTRA

Diabetes 2021;70(Supplement_1):740-P

https://doi.org/10.2337/db21-740-P

Published: 01 June 2021

View articletitled, 740-P: Proposed Biosimilar Gan & Lee Insulin Glargine (GL-GLA) Shows Pharmacokinetic (PK) and Pharmacodynamic (PD) Bioequivalence (BE) to U.S.- and EU-Licensed Insulin Glargine (IG)

Meeting Abstracts

738-P: Proposed Biosimilar Gan & Lee Insulin Aspart (GL-ASP) Shows Pharmacokinetic (PK) and Pharmacodynamic (PD) Bioequivalence (BE) to U.S.- and EU-Licensed Insulin Aspart (ASP)

LEONA PLUM-MOERSCHEL, ERNESTOS H. UHRMACHER, ERIC ZIJLSTRA, JIA LU, MICHAEL G. WILSON, MATTHEW E. BARTON, TIM HEISE

Diabetes 2021;70(Supplement_1):738-P

https://doi.org/10.2337/db21-738-P

Published: 01 June 2021

View articletitled, 738-P: Proposed Biosimilar Gan & Lee Insulin Aspart (GL-ASP) Shows Pharmacokinetic (PK) and Pharmacodynamic (PD) Bioequivalence (BE) to U.S.- and EU-Licensed Insulin Aspart (ASP)

Meeting Abstracts

736-P: Proposed Biosimilar Gan & Lee Insulin Lispro (GL-LIS) Shows Pharmacokinetic (PK) and Pharmacodynamic (PD) Bioequivalence (BE) vs. U.S.- and EU-Licensed Insulin Lispro (LIS)

ERIC ZIJLSTRA, TIM HEISE, MARCEL ERMER, JIA LU, MICHAEL G. WILSON, LEONA PLUM-MOERSCHEL

Diabetes 2021;70(Supplement_1):736-P

https://doi.org/10.2337/db21-736-P

Published: 01 June 2021

View articletitled, 736-P: Proposed Biosimilar Gan & Lee Insulin Lispro (GL-LIS) Shows Pharmacokinetic (PK) and Pharmacodynamic (PD) Bioequivalence (BE) vs. U.S.- and EU-Licensed Insulin Lispro (LIS)

Meeting Abstracts

951-P: Cotadutide (MEDI0382), a Dual Receptor Agonist with Glucagon-Like Peptide-1 and Glucagon Activity, Is Well Tolerated (<600 µG) with Robust Effects on Blood Glucose in Patients with T2DM

DARREN ROBERTSON, LARS HANSEN, MEENA JAIN, VICTORIA PARKER, MARCELLA PETRONE, TAO WANG, TIM HEISE, LUTZ JERMUTUS

Diabetes 2020;69(Supplement_1):951-P

https://doi.org/10.2337/db20-951-P

Published: 01 June 2020

View articletitled, 951-P: Cotadutide (MEDI0382), a Dual Receptor Agonist with Glucagon-Like Peptide-1 and Glucagon Activity, Is Well Tolerated (<600 µG) with Robust Effects on Blood Glucose in Patients with T2DM

Meeting Abstracts

25-OR: Acid–Base Changes during Diabetic Ketoacidosis (DKA) in T1DM with and without SGLT2 Inhibitor (SGLT2i)

INES MURSIC, EVA SVEHLIKOVA, WERNER REGITTNIG, THOMAS AUGUSTIN, CHRISTOPH MAGNES, ANITA EBERL, TIM HEISE, OLIVER KLEIN, MICHAEL WOLF, MARTINA URSCHITZ, MARTINA BRUNNER, HARALD SOURIJ, THOMAS PIEBER

Diabetes 2020;69(Supplement_1):25-OR

https://doi.org/10.2337/db20-25-OR

Published: 01 June 2020

View articletitled, 25-OR: Acid–Base Changes during Diabetic Ketoacidosis (DKA) in T1DM with and without SGLT2 Inhibitor (SGLT2i)

Update search

NARROW

Format

Journal

Article Type

Topics

Issue Section

Date

Availability

1975-LB: A Single Ascending Dose Study of a Once-Monthly Liraglutide Formulation in Participants with Type 2 Diabetes

802-P: Steady-State Pharmacokinetics and Glucodynamics of Once-Weekly Insulin Efsitora Alfa (Efsitora) in Individuals with Type 2 Diabetes (T2D)

141-OR: Safety, Tolerability, and Clinical Effects of Dapiglutide, a Once-Weekly GLP-1R/GLP-2R Agonist

1773-P: Effects of the Novel Long-Acting Amylin Analogue Petrelintide on Body Weight and Waist Circumference by Sex in a Phase 1 Trial

227-OR: Tirzepatide Reduces HbA1c and Body Weight Significantly More than Placebo Regardless of Insulin Sensitivity and Beta-Cell Function—Post Hoc Analysis from SURMOUNT-2

822-P: Influence of the Functionally Selective Insulin Analog NNC-965 vs. Insulin Glargine (IGla) on Cardiac Structure and Function

818-P: Effects of Insulin Efsitora Alfa (Efsitora) on Frequency and Severity of Hypoglycemia (Hypo) Under Conditions of Increased Hypo Risk Compared with Glargine in Type 2 Diabetes (T2D)

820-P: The Proposed Insulin Lispro Biosimilar GN1101DP Shows Pharmacokinetic (PK) and Pharmacodynamic (PD) Bioequivalence to Humalog in Caucasian and Chinese Healthy Subjects

92-LB: Safety, Tolerability, and Clinical Effects of ZP8396, a Novel Long-Acting Amylin Analog—A Single Ascending Dose Trial

967-P: Evaluation of CV and SD as Glucose Variability Metrics Based on Data from the GOLD and SILVER Trials

722-P: Tirzepatide Improves Multiple Aspects of Beta-Cell Function

714-P: Greater Improvement in Insulin Sensitivity Per Unit Weight Loss with Tirzepatide Compared with Selective GLP-1 Receptor Agonism

181-OR: Sympathetic Activity in Patients with Type 2 Diabetes Mellitus Treated with Empagliflozin or Hydrochlorothiazide

338-OR: Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People with T2D

197-OR: ADO09, a Coformulation of Insulin A21G and Pramlintide (Pram), Improves Blood Glucose Control and Reduces Body Weight in Subjects with T1D

740-P: Proposed Biosimilar Gan & Lee Insulin Glargine (GL-GLA) Shows Pharmacokinetic (PK) and Pharmacodynamic (PD) Bioequivalence (BE) to U.S.- and EU-Licensed Insulin Glargine (IG)

738-P: Proposed Biosimilar Gan & Lee Insulin Aspart (GL-ASP) Shows Pharmacokinetic (PK) and Pharmacodynamic (PD) Bioequivalence (BE) to U.S.- and EU-Licensed Insulin Aspart (ASP)

736-P: Proposed Biosimilar Gan & Lee Insulin Lispro (GL-LIS) Shows Pharmacokinetic (PK) and Pharmacodynamic (PD) Bioequivalence (BE) vs. U.S.- and EU-Licensed Insulin Lispro (LIS)

951-P: Cotadutide (MEDI0382), a Dual Receptor Agonist with Glucagon-Like Peptide-1 and Glucagon Activity, Is Well Tolerated (<600 µG) with Robust Effects on Blood Glucose in Patients with T2DM

25-OR: Acid–Base Changes during Diabetic Ketoacidosis (DKA) in T1DM with and without SGLT2 Inhibitor (SGLT2i)

Email alerts

Journals

Books

Clinical Compendia

News

Podcasts

Other

About

Resources

Update search

Email alerts

Journals

Books

Clinical Compendia

News

Podcasts

Other

About

Resources

This Feature Is Available To Subscribers Only